GlaxoSmithKline PLCGSK:LSE

9.00 / 0.56%
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 01 2016 15:57 BST.

Consensus recommendation

As of Jun 30, 2016, the consensus forecast amongst 27 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Share price forecast

The 23 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,506, with a high estimate of 1,865 and a low estimate of 1,272. The median estimate represents a 1.21% increase from the last price of 1,488. View Full Financials

High+16.9 %1,865
Med-5.6 %1,506
Low-20.3 %1,272


In 2015, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 23 analysts covering the company expect dividends of 0.82 GBP for the upcoming fiscal year, an increase of 2.13%. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 27, 2016, GlaxoSmithKline plc reported 1st quarter 2016 earnings of 0.198 per share. This result exceeded the 0.18 consensus of the 12 analysts covering the company and exceeded last year's 1st quarter results by 14.45%.
The next earnings announcement is expected on Jul 27, 2016. View Full Interim Financials

Average growth rate+5.26 %

GlaxoSmithKline plc reported annual 2015 earnings of 0.757 per share on Feb 03, 2016. View Full Annual Financials

Average growth rate-9.56 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


GlaxoSmithKline plc had 1st quarter 2016 revenues of 6.229bn. This bettered the 6.005bn consensus of the 12 analysts covering the company. This was 10.80% above the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+2.62 %

GlaxoSmithKline plc had revenues for the full year 2015 of 23.923bn. This was 3.99% above the prior year's results. View Full Annual Financials

Average growth rate-3.11 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.